The crunch is pushing up freight rates, costs that are likely to be passed on to consumers in higher retail prices.
Last month, trucking industry employment hit a six-year high of 1.4 million as carriers added 6,800 workers, the most since April 2013. The economy is picking up and businesses may still have been catching up after bad weather delayed deliveries early this year. But the job gains are at least partly fueled by the need for more drivers to offset the reduced hours, industry officials say.
"The government has forced drivers into basically a five-day work week," says David Osiecki, head of legislative affairs for the American Trucking Associations.
Hot Net Payout Yield Companies To Buy Right Now: American Apparel Inc (APP)
American Apparel, Inc. incorporated on July 22, 2005, is a vertically integrated manufacturer, distributor, and retailer of branded fashions basic apparel and accessories for women, men, children and babies. As of January 31, 2013, the Company had operated 251 retail stores in 20 countries. The Company also operates an e-commerce site that serves over 60 countries worldwide at www.americanapparel.com . In addition, American Apparel operates a business that supplies T-shirts and other casual wear to distributors and the imprintable industry. The Company operates in four business segment: U.S. Wholesale, U.S. Retail, Canada, and International.
The U.S. Wholesale segment consists of the Company's wholesale operations of sales of undecorated apparel products to distributors and third party screen printers in the United States, as well as its online consumer sales to United States customers. The U.S. Retail segment consists of the Company's retail store operations in the United States. The Canada segment consists of the Company's retail, wholesale and online consumer operations in Canada. As of December 31, 2012 , the retail operations in the Canada segment consisted of 35 retail stores. The International segment consists of the Company's retail, wholesale and online consumer operations outside of the United States, and Canada. As of December 31, 2012 , the retail operations in the International segment were consisted of 76 retail stores.
As of December 31, 2012 , the Company's retail operations consisted of 251 retail stores in 20 countries, including the United States, Canada, Mexico, Brazil, United Kingdom, Ireland, Austria, Belgium, Germany, France, Italy, the Netherlands, Spain, Sweden, Switzerland, Israel, Australia, Japan, South Korea and China. The Company's wholesale operations sell to over a dozen authorized distributors and approximately 10,000 screen printers and advertising specialty companies. The Company operates 12 online stores in the United States, Canada, the U! nited Kingdom, Continental Europe, Switzerland, Japan, South Korea, Australia, Mexico, Brazil, Singapore and Hong Kong.
The Company competes with The Gap, Urban Outfitters, H&M, Uniqlo, Forever 21, Gildan Activewear, HanesBrands, Russell Athletic and Fruit of the Loom.
Advisors' Opinion:- [By Michael Hamlett Jr]
American Apparel (APP) is an American clothing manufacturer, distributor and retailer. APP suspended its CEO, Dov Charney, but has kept him as a consultant pending further investigation into his conduct. To say that APP is struggling would be a huge understatement. If New York investment firm Standard General didn't acquire Charney's 44% stake in the company for $25 million and pay for a $10 million loan at 20% interest from Lion Capital, the company would probably be filing for brankruptcy.
Hot Net Payout Yield Companies To Buy Right Now: Global Sources Ltd.(GSOL)
Global Sources Ltd. operates as a business-to-business media company primarily in greater China. It provides sourcing information to volume buyers and integrated marketing services to suppliers. The company offers trade information using online media, print media, and face-to-face events. Its products and services comprise online product information and listing services; organizing trade shows; and advertising and marketing creative services; trade publications in print and digital formats; and china sourcing reports. The company uses English-language media to facilitate trade from Greater China to the world, as well as utilizes Chinese-language media to enable companies to sell to, and within, Greater China. It delivers information on approximately 5.7 million products and approximately 262,000 suppliers annually through 14 online marketplaces, 13 monthly print and 18 digital magazines, approximately 90 sourcing research reports, and 73 specialized trade shows a year in 9 cities. The company was founded in 1970 and is based in Hamilton, Bermuda.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Global Sources (Nasdaq: GSOL ) , whose recent revenue and earnings are plotted below.
10 Best India Stocks To Invest In Right Now: Kazakhmys PLC (KAZ)
Kazakhmys PLC, along with its subsidiaries, is natural resource company focused on the production of copper. It is engaged in the production of copper and other metals as by-products, including zinc, silver and gold, and power generation. The Company�� segments are Kazakhmys Mining, which is engaged in the exploration, evaluation, development, mining and processing of mineral resources and sale of the metal products; MKM, which operates in Germany, where it manufactures copper and copper alloy semi-finished products; Kazakhmys Power, which operates in Kazakhstan, and consists of its captive power stations, the Ekibastuz GRES-1 coal-fired power station joint venture, and Kazakhmys Petroleum business, which holds a license to conduct oil and gas exploration and development activity in the East Akzhar Exploration Block in western Kazakhstan. In May 2011, the Company completed the disposal of the small Maikuben West coal mine. Advisors' Opinion:- [By Alexis Xydias]
Kazakh miners ENRC (ENRC) and Kazakhmys Plc (KAZ) slid 3.7 percent to 204 pence, and 2.4 percent to 258.7 pence, respectively, as the FTSE 350 Mining Index fell for the third time this week. African Barrick Gold Plc tumbled 7.7 percent to 96 pence, a record low.
- [By Sarah Jones]
Kazakhmys Plc (KAZ) tumbled 13 percent to 233.7 pence after the founders of Eurasian Natural Resources Corp. (ENRC) and the Kazakhstan government offered to buy ENRC with cash and Kazakhmys shares in a bid that values the company at 3.04 billion pounds ($4.7 billion). ENRC slid 1.4 percent to 213.8 pence.
Hot Net Payout Yield Companies To Buy Right Now: Harmony Gold Mining Co. Ltd. (HMY)
Harmony Gold Mining Company Limited engages in the exploration, extraction, processing, and smelting of gold in South Africa and Papua New Guinea. The company has approximately 10 underground operations; and various surface operations, including an open cast mine and 9 processing plants, which are located in goldfields in the Witwatersrand basin of South Africa, as well as the Kraaipan Greenstone Belt. It also explores for silver, copper, and molybdenum through its Papua New Guinea projects. The company also owns interest in various exploration and development prospects, and 1 operating mine primarily at the Hidden Valley and Wafi Golpu projects; and a 100% interests in 3 projects, including the Mount Hagen in the Western Highlands, Amanab in the Sandaun province, and Tari in the Southern Highlands province in Papua New Guinea. As of June 30, 2012, its prospecting interest comprised 75,249 hectares in South Africa and 898,400 hectares in Papua New Guinea. Harmony Gold Mini ng Company Limited was founded in 1950 and is headquartered in Randfontein, South Africa.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Basic Materials shares gained around 0.24 percent in trading on Wednesday. Meanwhile, top gainers in the sector included Harmony Gold Mining Company (NYSE: HMY), up 4.1 percent, and Thompson Creek Metals Company (NYSE: TC), up 3.8 percent. In trading on Wednesday, cyclical consumer goods & services shares were relative laggards, down on the day by about 0.36 percent. - [By Rich Duprey]
Mining operations have long been subject to the vagaries of strikes and violence in South Africa. Harmony Gold (NYSE: HMY ) suspended its operations at�Kusasalethu because of security concerns, Gold Fields (NYSE: GFI ) lost 35,000 ounces of production and had its credit rating reduced by Standard & Poor's because of labor unrest (and reduced its full-year production forecast by 200,000 ounces), and Xstrata has had to halt activity several times as a result of union violence.
Hot Net Payout Yield Companies To Buy Right Now: Ambit Biosciences Corp (AMBI)
Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.
Quizartinib
The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.
AC410
The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.
CSF1R Program
The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.
The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.
Advisors' Opinion:- [By Wallace Witkowski]
Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.
No comments:
Post a Comment